Guha Venkatraman, MD
Neurology · Livingston, NJNPI 1356517593
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,780 of the $10,976 with a category attached, or 61.8%. AbbVie accounts for 79.1% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2020 at $8,030 and has fallen 88.3% since, to $942 in 2025.
Across 197 payments — averaging $55.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- AstraZeneca$398
- UCB, Inc.$206
- Pfizer$187
- Lilly USA, LLC$179
- Teva Pharmaceuticals USA, Inc.$143
- plus $1K from 30 others
What the payments were for
- Speaking & faculty fees$6,78062%
- Travel & lodging$7447%
- Food & beverage$3,41731%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $8,678 |
| AstraZeneca(2 entities) | 10 | $398 |
| UCB, Inc. | 6 | $206 |
| Pfizer | 11 | $187 |
| Lilly USA, LLC | 12 | $179 |
| Teva Pharmaceuticals USA, Inc. | 10 | $143 |
| Nevro Corp. | 3 | $118 |
| GE HealthCare | 5 | $90 |
| MDD US Operations, LLC | 4 | $81 |
| Argenx US, Inc. | 4 | $77 |
| SK Life Science, Inc. | 4 | $70 |
| Alnylam Pharmaceuticals Inc. | 3 | $59 |
| Tris Pharma Inc | 4 | $55 |
| Grifols USA, LLC | 3 | $48 |
| Scilex Pharmaceuticals Inc. | 3 | $46 |
| Medtronic | 1 | $46 |
| Lundbeck LLC | 3 | $45 |
| Amgen | 3 | $45 |
| Supernus Pharmaceuticals, Inc. | 3 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Novartis | 2 | $36 |
| Abbott | 2 | $34 |
| Eisai Inc. | 2 | $31 |
| Mallinckrodt Enterprises LLC | 2 | $30 |
| Sanofi | 1 | $27 |
| C2n Diagnostics, LLC | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Life Molecular Imaging Ltd | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,976 in reported general payments places this provider in the 75th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 24 | $365,891 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $115,636 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $17,941 |
| UbrelvyUbrogepant | 11 | $15,148 |
| QuliptaAtogepant | 12 | $14,473 |
| Gabapentin | 128 | $2,219 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 86 | $2,113 |
| Donepezil Hcl | 92 | $2,011 |
| AmantadineAmantadine Hcl | 20 | $1,766 |
| Memantine Hcl | 60 | $1,742 |
| Pyridostigmine Bromide | 13 | $1,239 |
| DilantinPhenytoin Sodium Extended | 12 | $1,222 |
| Entacapone | 15 | $975 |
| Pregabalin | 27 | $796 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $8,678 | $29,62123 claims |
| PfizerDilantin | $187 | $1,22212 claims |
| Upsher-smith Laboratories LLCTopiramate | $15 | $5312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 521 neurology providers in New Jersey.
Other neurology in Livingston
- Matthew TremblayLivingston$35K
- Yanchun ZhangLivingston$35K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.